SCHEMBL6536653

SCHEMBL6536653

CCCc1nc(Cl)c(C(=O)O)n1Cc1ccc(-c2ccccc2)c(-c2nnn[nH]2)c1

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 8/20 0.57
AGTR2 P50052 6/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3427175 0.95 AGTR1 (0.64) AGTR1AGTR2
SCHEMBL855 0.92 AGTR1 (0.64) AGTR1AGTR2
SCHEMBL6536063 0.90 AGTR1 (0.51) AGTR1AGTR2
SCHEMBL7998832 0.90 AGTR1 (0.63) AGTR1AGTR2
SCHEMBL8469323 0.88 AGTR1 (0.46) AGTR1AGTR2
SCHEMBL5138819 0.87 AGTR1 (0.64) AGTR1AGTR2
SCHEMBL7171699 0.87 AGTR1 (0.57) AGTR1AGTR2
SCHEMBL8070062 0.87 AGTR1 (0.57) AGTR1AGTR2
Carboxylic Acid Metabolite SCHEMBL179 0.87 AGTR2 (0.72) AGTR1AGTR2
SCHEMBL9328849 0.86 AGTR1 (0.64) AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6300356-B1 ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST MERCK & CO., INC. 2001-10-09 US claimed
US-6201002-B1 ADMINISTERING IMIDAZOLE DERIVATIVE TO TREAT CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS MERCK & CO., INC. 2001-03-13 US claimed
EP-1059843-A1 METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST Merck & Co., Inc. (US) 2000-12-20 EP claimed
US-5962500-A HYPOSENSITVE AGENT MERCK SHARP & DOHME CORP. 1999-10-05 US claimed
WO-1999043210-A1 METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST MERCK & CO., INC. (US) 1999-09-02 WO claimed
WO-1995026724-A1 IMPROVEMENT OF INSULIN SENSITIVITY WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES EIDE IVAR KONRAD (NO) 1995-10-12 WO claimed
EP-0533840-A1 TREATMENT OF CHRONIC RENAL FAILURE WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS. DU PONT (US) 1993-03-31 EP claimed
EP-0324377-A2 Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-19 EP claimed
EP-0754042-A4 TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES MERCK & CO INC (US) 2004-06-23 EP disclosed
US-6300356-B1 ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST MERCK & CO., INC. 2001-10-09 US disclosed
US-6201002-B1 ADMINISTERING IMIDAZOLE DERIVATIVE TO TREAT CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS MERCK & CO., INC. 2001-03-13 US disclosed
EP-1059843-A1 METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST Merck & Co., Inc. (US) 2000-12-20 EP disclosed
WO-1999043210-A1 METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST MERCK & CO., INC. (US) 1999-09-02 WO disclosed
US-5663187-A ANTICHOLESTEROL AGENTS AND ENZYME INHIBITORS MERCK & CO., INC. (US) 1997-09-02 US disclosed
EP-0754042-A1 TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES MERCK & CO. INC. (US) 1997-01-22 EP disclosed
WO-1995026724-A1 IMPROVEMENT OF INSULIN SENSITIVITY WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES EIDE IVAR KONRAD (NO) 1995-10-12 WO disclosed
WO-1995026188-A1 TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES MERCK & CO., INC. (US) 1995-10-05 WO disclosed